Heartseed Initiates World’s First Catheter-Based iPS Heart Therapy Study
TOKYO, Japan, June 2026 Heartseed Inc. announced the successful treatment of the first patient in its Phase I/II EMERALD...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
TOKYO, Japan, June 2026 Heartseed Inc. announced the successful treatment of the first patient in its Phase I/II EMERALD...
HONG KONG, June 8, 2026 Ascletis Pharma Inc. presented new clinical and preclinical data from its expanding obesity pipeline...
SCHLIEREN / ZURICH, Switzerland, June 5, 2026 Memo Therapeutics AG announced additional positive analyses from its Phase II SAFE...
SHANGHAI, China, June 8, 2026 OriCell Therapeutics has achieved a major regulatory and clinical milestone with the National Medical...
CHENGDU, China, May 29, 2026 Kelun-Biotech has presented pivotal Phase II clinical trial results for its next-generation selective RET...
TORONTO, May 22, 2026 Arch Biopartners announced that Royal Columbian Hospital (RCH) in British Columbia has dosed its first...
ALBANY, N.Y., May 19, 2026 Curia Global, Inc. has announced the completion of a major upgrade to its aseptic...
MINNEAPOLIS, Minn., May 19, 2026 MEKanistic Therapeutics has announced that the U.S. Food and Drug Administration (FDA) cleared the...
BERLIN, Germany, May 18, 2026 Bayer has announced that the U.S. Food and Drug Administration (FDA) granted Priority Review...
NIJMEGEN, The Netherlands, May 19, 2026 Khondrion announced that the first patient has been dosed in the Phase II...
